LLY

736.79

-1.55%↓

JNJ

153.79

+0.44%↑

ABBV

183.08

-0.59%↓

NVO

68.99

-0.04%↓

UNH

303.99

-3.64%↓

LLY

736.79

-1.55%↓

JNJ

153.79

+0.44%↑

ABBV

183.08

-0.59%↓

NVO

68.99

-0.04%↓

UNH

303.99

-3.64%↓

LLY

736.79

-1.55%↓

JNJ

153.79

+0.44%↑

ABBV

183.08

-0.59%↓

NVO

68.99

-0.04%↓

UNH

303.99

-3.64%↓

LLY

736.79

-1.55%↓

JNJ

153.79

+0.44%↑

ABBV

183.08

-0.59%↓

NVO

68.99

-0.04%↓

UNH

303.99

-3.64%↓

LLY

736.79

-1.55%↓

JNJ

153.79

+0.44%↑

ABBV

183.08

-0.59%↓

NVO

68.99

-0.04%↓

UNH

303.99

-3.64%↓

Search

Compugen Ltd

Ouvert

1.38 2.22

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.31

Max

1.41

Chiffres clés

By Trading Economics

Revenu

-7.4M

-6.1M

Ventes

-16M

1.5M

P/E

Moyenne du Secteur

60.333

54.533

BPA

-0.08

Marge bénéficiaire

-415.84

Employés

74

EBITDA

-12M

-7.5M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+183.69% upside

Dividendes

By Dow Jones

Prochains Résultats

5 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-630M

130M

Ouverture précédente

-0.84

Clôture précédente

1.38

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Compugen Ltd Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

20 mai 2025, 20:54 UTC

Acquisitions, Fusions, Rachats

PNC to Buy Private-Equity Agent Aqueduct Capital

20 mai 2025, 20:50 UTC

Résultats

Palo Alto Networks Posts Higher 3Q Sales, Profit Slips

20 mai 2025, 23:48 UTC

Acquisitions, Fusions, Rachats

Kraft Heinz Evaluating Strategic Transactions, Berkshire Hathaway Steps Away From Board -- Update

20 mai 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound Amid Tariff Uncertainty -- Market Talk

20 mai 2025, 23:39 UTC

Market Talk

Gold Steady, Supported by Lingering U.S. Fiscal-Deficit Concerns -- Market Talk

20 mai 2025, 23:08 UTC

Market Talk

James Hardie's Repair & Remodel Outlook Surprises RBC -- Market Talk

20 mai 2025, 22:46 UTC

Acquisitions, Fusions, Rachats

Gold Road: Takeover Remains Subject to Independent Expert Findings; Shareholder, Court Approval

20 mai 2025, 22:45 UTC

Acquisitions, Fusions, Rachats

Gold Road: Notified Australia Government Has No Objections to Takeover by Gold Fields

20 mai 2025, 22:44 UTC

Actualités

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- 2nd Update

20 mai 2025, 22:20 UTC

Actualités

In Latest EV Pullback, Ford to Share Battery Plant With Nissan -- WSJ

20 mai 2025, 22:00 UTC

Résultats

ZTO Express (Cayman) 1Q Adj EPS 37c >ZTO

20 mai 2025, 22:00 UTC

Résultats

ZTO Express (Cayman) 1Q EPS 34c >ZTO

20 mai 2025, 22:00 UTC

Résultats

ZTO Express (Cayman) 1Q Rev $1.5B >ZTO

20 mai 2025, 21:44 UTC

Résultats

James Hardie Industries 4Q Adj EPS 36c >JHX

20 mai 2025, 21:44 UTC

Résultats

James Hardie Industries: Sees FY26 North America Net Sales Growth Up Low Single Digits >JHX

20 mai 2025, 21:44 UTC

Résultats

James Hardie Industries 4Q EPS 10c >JHX

20 mai 2025, 21:44 UTC

Résultats

James Hardie Industries 4Q Sales $972M >JHX

20 mai 2025, 20:52 UTC

Actualités

Elon Musk to Cut Back Political Spending -- 3rd Update

20 mai 2025, 20:52 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 mai 2025, 20:52 UTC

Market Talk

Mexican Stocks Near Record High As Trade Concerns Ease -- Market Talk

20 mai 2025, 20:30 UTC

Acquisitions, Fusions, Rachats

PNC Financial: Aqueduct Acquisition Expected to Close in Mid-Summer, Terms Won't be Disclosed >PNC

20 mai 2025, 20:28 UTC

Acquisitions, Fusions, Rachats

PNC Bank Agrees To Acquire Aqueduct Capital Group To Complement Harris Williams Capabilities >PNC

20 mai 2025, 20:23 UTC

Acquisitions, Fusions, Rachats

Tesla CEO Musk Says He Plans to Be at White House for a Couple Days Every Few Weeks

20 mai 2025, 20:22 UTC

Résultats

XP 1Q Adj EPS BRL2.29 >XP

20 mai 2025, 20:22 UTC

Résultats

XP 1Q Rev BRL4.345B >XP

20 mai 2025, 20:21 UTC

Acquisitions, Fusions, Rachats

Tesla CEO Musk: 'We're in the Big Bang of Intelligence Explosion'

20 mai 2025, 20:20 UTC

Actualités

Fed's Bostic Signals Longer Delay in Cutting Interest Rates -- Barrons.com

20 mai 2025, 20:19 UTC

Acquisitions, Fusions, Rachats

Tesla CEO Musk Says He Doesn't Currently Have Plans to Merge Tesla, xAI

20 mai 2025, 20:11 UTC

Actualités

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- Update

20 mai 2025, 20:09 UTC

Résultats

Palo Alto Networks 3Q Remaining Performance Obligation $13.5 B >PANW

Comparaison

Variation de prix

Compugen Ltd prévision

Objectif de Prix

By TipRanks

183.69% hausse

Prévisions sur 12 Mois

Moyen 4 USD  183.69%

Haut 4 USD

Bas 4 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

3 ratings

3

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

1.25 / 1.48Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Very Strong Bearish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.